NVIDIA launches Jetson Thor robotics computers for physical AI systems
Investing.com - Oppenheimer initiated coverage on Procept BioRobotics Corp (NASDAQ:PRCT) with a Perform rating on Monday, citing a balanced risk-reward assessment at current levels. The company, currently valued at $3.2 billion, has maintained strong revenue growth of 59.36% over the last twelve months, according to InvestingPro data.
The research firm highlighted Procept’s pioneering Aquablation technology, an image-guided high-pressure, non-thermal waterjet ablation system specifically designed for treating benign prostatic hyperplasia (BPH), a condition causing prostate enlargement in men.
Oppenheimer noted that Aquablation’s clinical value has been "robustly demonstrated in multiple clinical trials," with the company achieving an impressive four-year revenue compound annual growth rate of approximately 75%.
The analyst views the company’s fiscal year 2025 revenue guidance of $323 million as conservative and expects Procept to beat expectations in the second quarter.
Despite positive views on the underlying science, Oppenheimer expressed the need to "get comfortable with utilization in a fragmented market" and cited concerns about potential risks from a 20% cut to physician payment rates.
In other recent news, Procept BioRobotics Corp reported first-quarter 2025 earnings that exceeded analysts’ expectations. The company posted an earnings per share (EPS) of -$0.45, surpassing the forecasted -$0.4907, and achieved a revenue of $69.2 million, which was above the anticipated $65.43 million. This represents a significant year-over-year revenue growth of 55%, with U.S. revenue increasing by 50%. Leerink Partners adjusted its price target for Procept BioRobotics to $90.00 from $91.00, while maintaining an Outperform rating, citing a positive outlook on the company’s potential in the prostate cancer space. Meanwhile, Truist Securities kept its buy rating and $70.00 price target, highlighting positive utilization trends and a strong capital pipeline. Procept BioRobotics plans to expand its international presence, particularly in the UK and Japan, and continues to see strong demand for its robotic systems and handpieces. The company set a full-year revenue guidance of $323 million, reflecting a 44% increase year-over-year, and aims to sell 210 new robotic systems in 2025. These developments underscore Procept BioRobotics’ strategic focus and growth potential in the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.